Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

869 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-beta type II receptor kinase and mixed lineage kinase-7.
Li HY, Wang Y, Heap CR, King CH, Mundla SR, Voss M, Clawson DK, Yan L, Campbell RM, Anderson BD, Wagner JR, Britt K, Lu KX, McMillen WT, Yingling JM. Li HY, et al. Among authors: voss m. J Med Chem. 2006 Mar 23;49(6):2138-42. doi: 10.1021/jm058209g. J Med Chem. 2006. PMID: 16539403
Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.
Li HY, McMillen WT, Heap CR, McCann DJ, Yan L, Campbell RM, Mundla SR, King CH, Dierks EA, Anderson BD, Britt KS, Huss KL, Voss MD, Wang Y, Clawson DK, Yingling JM, Sawyer JS. Li HY, et al. Among authors: voss md. J Med Chem. 2008 Apr 10;51(7):2302-6. doi: 10.1021/jm701199p. Epub 2008 Mar 4. J Med Chem. 2008. PMID: 18314943
Discovery of a highly potent orally bioavailable imidazo-[1, 2-a]pyrazine Aurora inhibitor.
Yu T, Zhang Y, Kerekes AD, Tagat JR, Doll RJ, Xiao Y, Esposite S, Hruza A, Belanger DB, Voss M, Rainka MP, Basso A, Liu M, Liang L, Sui N, Prelusky D, Rindgen D, Zhang L. Yu T, et al. Among authors: voss m. Bioorg Med Chem Lett. 2018 May 1;28(8):1397-1403. doi: 10.1016/j.bmcl.2018.02.037. Epub 2018 Feb 23. Bioorg Med Chem Lett. 2018. PMID: 29545102
Prospective Study of Patient, Nursing, and Oncology Provider Perspectives on Telemedicine Visits for Renal Cell Carcinoma Clinical Trials.
Doshi SD, Knezevic A, Gonzalez C, Fischer P, Goodman R, Gornell S, Patel S, Puzio C, Ritea A, Lee CH, Evans L, Voss MH, Motzer RJ, Kotecha RR. Doshi SD, et al. Among authors: voss mh. Clin Genitourin Cancer. 2024 Nov 13;23(1):102268. doi: 10.1016/j.clgc.2024.102268. Online ahead of print. Clin Genitourin Cancer. 2024. PMID: 39616970
Five-Year Prostate-Specific Membrane Antigen Positron Emission Tomography-Based Outcomes of Spot-Scanning Proton Radiation Therapy for Localized Prostate Cancer: A Single Institution Experience.
Sperduto W, Voss MM, Laughlin B, Toesca DAS, Wong WW, Keole SR, Rwigema JM, Yu NY, Schild SE, James SE, Daniels TB, DeWees TA, Vargas CE. Sperduto W, et al. Among authors: voss mm. Adv Radiat Oncol. 2024 Sep 18;9(11):101639. doi: 10.1016/j.adro.2024.101639. eCollection 2024 Nov. Adv Radiat Oncol. 2024. PMID: 39610799 Free PMC article.
GOLPH3 and GOLPH3L maintain Golgi localization of LYSET and a functional mannose 6-phosphate transport pathway.
Brauer BK, Chen Z, Beirow F, Li J, Meisinger D, Capriotti E, Schweizer M, Wagner L, Wienberg J, Hobohm L, Blume L, Qiao W, Narimatsu Y, Carette JE, Clausen H, Winter D, Braulke T, Jabs S, Voss M. Brauer BK, et al. Among authors: voss m. EMBO J. 2024 Dec;43(24):6264-6290. doi: 10.1038/s44318-024-00305-z. Epub 2024 Nov 25. EMBO J. 2024. PMID: 39587297 Free PMC article.
Short-course hypofractionated proton beam therapy, incorporating 18F-DOPA PET and contrast-enhanced MRI targeting, for patients aged 65 years and older with newly diagnosed glioblastoma: a single-arm phase 2 trial.
Vora S, Pafundi D, Voss M, Buras M, Ashman J, Bendok B, Breen W, Hu L, Kizilbash S, Laack N, Liu W, Mahajan A, Mrugala M, Porter A, Ruff M, Sio T, Uhm J, Yang M, Brinkmann D, Brown P. Vora S, et al. Among authors: voss m. Lancet Oncol. 2024 Dec;25(12):1625-1634. doi: 10.1016/S1470-2045(24)00585-0. Epub 2024 Nov 18. Lancet Oncol. 2024. PMID: 39571596 Clinical Trial.
Frequency and clinical associations of common mental disorders in adults with high-grade glioma-A multicenter study.
Singer S, Schranz M, Hippler M, Kuchen R, Weiß Lucas C, Meixensberger J, Fehrenbach MK, Keric N, Mitsdoerffer M, Gempt J, Coburger J, Kessler AF, Wehinger J, Misch M, Onken J, Rapp M, Voß M, Nadji-Ohl M, Mehlitz M, Tatagiba M, Tabatabai G, Renovanz M. Singer S, et al. Among authors: voss m. Cancer. 2024 Nov 17. doi: 10.1002/cncr.35653. Online ahead of print. Cancer. 2024. PMID: 39550627
Behavior change theory and behavior change technique use in cancer rehabilitation interventions: a secondary analysis.
Voss ML, Brick R, Padgett LS, Wechsler S, Joshi Y, Ammendolia Tomé G, Arbid S, Campbell G, Campbell KL, El Hassanieh D, Klein C, Lam A, Lyons KD, Sabir A, Sleight AG, Jones JM. Voss ML, et al. Eur J Phys Rehabil Med. 2024 Dec;60(6):1036-1050. doi: 10.23736/S1973-9087.24.08452-1. Epub 2024 Oct 24. Eur J Phys Rehabil Med. 2024. PMID: 39445735 Free article.
869 results